Images List Premium Download Classic

Inflammatory Disease

Inflammatory Disease-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Il-33 antagonists and uses thereof
July 20, 2017 - N°20170204158

The present invention provides interleukin-33 (il-33) antagonists comprising one or more il-33-binding domains and one or more multimerizing domains and methods of using the same. According to certain embodiments of the invention, the il-33-binding domains can comprise an il-33-binding portion of an st2 protein and/or an extracellular portion of an il-1racp protein. The il-33 antagonists ...
Anti-inflammatory properties of a surface protein of propionibacterium freudenreichii
Institut Pasteur De Lille (ipl)
July 20, 2017 - N°20170204145

Disclosed is a polypeptide including or consisting of the amino acid sequence seq id no:1, for use in the treatment or prevention of an inflammatory disease. It further encompasses a nucleic acid sequence encoding a polypeptide, a vector including a nucleic acid and a host cell including a nucleic acid sequence and/or a vector, for use in the treatment ...
Inhibitors of histone deacetylase
Rodin Therapeutics, Inc.
July 20, 2017 - N°20170204070

This invention provides compounds that are inhibitors of hdac2. The compounds (e. G., compounds according to formula (i), (ii), (iia), (iii), (iv), (v), or (vi)) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological ...
Inflammatory Disease Patent Pack
Download 291+ patent application PDFs
Inflammatory Disease Patent Applications
Download 291+ Inflammatory Disease-related PDFs
For professional research & prior art discovery
inventor
  • 291+ full patent PDF documents of Inflammatory Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Aminoacyl trna synthetases for modulating inflammation
Atyr Pharma, Inc.
July 20, 2017 - N°20170202933

Inflammatory and other cellular response-modulating compositions are provided comprising aminoacyl-trna synthetase polypeptides, including active fragments and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of inflammation, such as inflammatory diseases or conditions.
Quinazolin-4 (3h)-one derivatives used as p13 kinase inhibitors
Atyr Pharma, Inc.
July 20, 2017 - N°20170202841

And to compositions comprising the same and to the use of the compound and to compositions of the compound in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compound.
Compounds for the treatment of cancer and inflammatory diseases
C2 Pharmaceuticals, Llc
July 20, 2017 - N°20170202812

The present invention relates to novel compounds and pharmaceutical compositions thereof which may be useful in the treatment and/or prevention of various conditions. The present invention also provides methods of preparing such compounds and compositions, and methods of using the same.
Inflammatory Disease Patent Pack
Download 291+ patent application PDFs
Inflammatory Disease Patent Applications
Download 291+ Inflammatory Disease-related PDFs
For professional research & prior art discovery
inventor
  • 291+ full patent PDF documents of Inflammatory Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Psgl-1 modulators and uses thereof
Sanford-burnham Medical Research Institute
July 13, 2017 - N°20170198047

The present invention relates to the seminal discovery that p-selectin glycoprotein ligand-1 (psgl-1) modulates the immune system and immune responses. Specifically, the present invention provides psgl-1 agonists and antagonists which increase the survival of multifunctional t cells and viral clearance. The present invention further provides methods of treating infectious diseases, cancer and immune and inflammatory diseases and disorders using a ...
Compositions and methods for safe and effective immunotherapy
Theramab Llc
July 13, 2017 - N°20170198044

This invention relates to methods and compositions that are useful for the treatment of various diseases, including inflammatory diseases. The invention relates to, in part, doses and regimens for safer immunotherapy in the treatment of these diseases, including, for example, safe treatments with anti-cd28 antibodies.
Compositions and methods for treating tumors and immune based inflammatory diseases
The Schepens Eye Research Institute, Inc.
July 13, 2017 - N°20170198026

This present invention provides compositions and methods for treating cancer and immune inflammatory disorders by modulating emr2 signaling pathway.
Soluble tnf receptors and their use in treatment of disease
Roche Innovation Center Copenhagen A/s
July 13, 2017 - N°20170198024

The present invention relates to tumor necrosis factor (tnf) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (tnfrs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to tnf and prevent tnf from signaling to cells. In particular, the proteins are mammalian tnfrs that lack exon 7 and which ...
A quinoline derivative for the treatment of inflammatory diseases and aids
Universite De Montpellier
July 13, 2017 - N°20170197938

The present invention relates to a compound of formula (1) in the form of a base or addition salt with an acid, particularly a pharmaceutically acceptable acid. It further relates to a pharmaceutical composition including the compound and at least one pharmaceutically acceptable excipient, to a process for preparing said compound and to a corresponding intermediate compound.
Treatment of inflammatory demyelinating disease with agonists of farnesoid x receptor
The Board Of Trustees Of The Leland Stanford Junior University
July 13, 2017 - N°20170196893

Provided herein are methods and compositions for treating demyelinating inflammatory diseases by administering to the subject an effective dose on an fxr agonist.
Heterocyclic gsk-3 allosteric modulators
Consejo Superior De Investigaciones Cientificas (csic)
July 13, 2017 - N°20170196850

The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (gsk-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein gsk-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.
Inflammatory Disease Patent Pack
Download 291+ patent application PDFs
Inflammatory Disease Patent Applications
Download 291+ Inflammatory Disease-related PDFs
For professional research & prior art discovery
inventor
  • 291+ full patent PDF documents of Inflammatory Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
Incozen Therapeutics Pvt. Ltd.
July 13, 2017 - N°20170196843

The present disclosure relates to pharmaceutical compositions useful for (and to a method of) treating autoimmune, respiratory and/or inflammatory diseases and conditions. The method involves administering to a subject in need thereof roflumilast n-oxide by inhalation. The present disclosure particularly relates to the treatment of asthma and chronic obstructive pulmonary disease (copd) by administering roflumilast n-oxide by inhalation.
Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
Roche Innovation Center Copenhagen A/s
July 06, 2017 - N°20170191067

Methods and compositions are disclosed for controlling expression of tnf receptors (tnfr1 and tnfr2) and of other receptors in the tnfr superfamily using compounds that modulate splicing of pre-mrna encoding these receptors. More specifically these compounds cause the removal of the transmembrane domains of these receptors and produce soluble forms of the receptor which act as an antagonist to reduce ...
Rna editing biomarkers for diagnosis, pharmacological screening and prognostication in cancer
Regents Of The University Of California
July 06, 2017 - N°20170191057

Compositions and methods for expanding cd34+ cells, performing research related to cancer stem cells, rna-editing enzymes and for monitoring, diagnosing and treating, ameliorating and preventing diseases such as cancers or inflammatory diseases.
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
Novo Nordisk A/s
July 06, 2017 - N°20170190775

The invention relates to antibodies that are capable of specifically binding trem-1 and preventing the activation of trem-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
Transcriptional signature for chlamydial pelvic inflammatory disease
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
June 29, 2017 - N°20170183732

Methods are provided herein for determining the likelihood that a subject, such as an asymptomatic subject, has chlamydial pelvic inflammatory disease. In some embodiments, the method can determine the likelihood that a pharmaceutical agent is effective for treating a subject that has chlamydial pelvic inflammatory disease. In other specific non-limiting examples, the method predicts endometritis and elevated pathogen burden. The ...
Inhibitors of cyclin-dependent kinase 7 (cdk7)
Syros Pharmaceuticals, Inc.
June 29, 2017 - N°20170183355

The present invention provides novel compounds of formula (i) and formula (ii) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e. G., cancers (e. G., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and ...
Inhibitors of bruton's tyrosine kinase
Chugai Pharmaceutical Inc.
June 29, 2017 - N°20170183327

This application discloses compounds according to generic formula (i): wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant b-cell activation. Also disclosed ...
Methods of treating atopic dermatitis with il-31 monoclonal antibodies
Zymogenetics, Inc.
June 29, 2017 - N°20170182160

Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for il-31 are provided. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human il-31. Cdr regions derived from same or different immunoglobulin moieties are provided. Also provided are single chain polypeptides wherein vh and vl domains are attached. The sfv molecules can include ...
Loading